On July 13, the Food and Drug Administration (FDA) made a significant announcement, stating that it has granted approval for the sale of a birth control pill without the requirement of a prescription in the United States. Presently, a woman in the United States who wishes to use birth control pills is required to obtain a prescription from a doctor. The FDA approval for the sale of a birth control pill without a prescription represents a major shift in this requirement. The approved pill, known as Opill, is a progestin-only contraceptive. Dr. Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, highlighted that with this approval, a nonprescription daily oral contraceptive will be accessible for the first time as an option for millions in the United States.
National Catholic Reporter reports:
The Food and Drug Administration announced July 13 it approved the sale of a birth control pill without a prescription for the first time in the United States, a move that will increase the availability of oral contraception and impact ongoing debates about abortion policy.
In a statement, Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said the approval of Opill, a progestin-only pill, “marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States.”
“When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy,” Cavazzoni said.
Currently, a woman seeking to use birth control pills must do so with a doctor’s prescription.
While some have called for expanded access to contraception in the wake of the U.S. Supreme Court’s June 2022 decision in Dobbs v. Jackson Women’s Health Organization, which overturned the high court’s jurisprudence on abortion as a constitutional right, others have argued that proliferating contraception without medical supervision could lead to more unintended pregnancies.
Opill is expected to be available for retail sale in the U.S. in the first quarter of 2024, its maker, Perrigo, said in a statement.
Read the full article here.